These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26942019)

  • 21. The role of cardiac resynchronization therapy for arterial switch operations complicated by complete heart block.
    Mah DY; Alexander ME; Banka P; Abrams DJ; Triedman JK; Walsh EP; Fynn-Thompson F; Mayer JE; Cecchin F
    Ann Thorac Surg; 2013 Sep; 96(3):904-9. PubMed ID: 23932320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late recovery of atrioventricular conduction after pacemaker implantation for complete heart block associated with surgery for congenital heart disease.
    Batra AS; Wells WJ; Hinoki KW; Stanton RA; Silka MJ
    J Thorac Cardiovasc Surg; 2003 Jun; 125(6):1291-3. PubMed ID: 12830046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone.
    Yasui T; Shioyama W; Oboshi M; Nishikawa T; Kamada R; Oka T; Fujita M
    J Cardiol Cases; 2020 May; 21(5):197-199. PubMed ID: 32373247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib induced cardiotoxicity in a multiple myeloma patient.
    Méndez-Toro A; Díaz-Brochero C; Acosta-Gutiérrez E
    Cardiooncology; 2020; 6():17. PubMed ID: 32944287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
    Yamaguchi T; Sasaki M; Itoh K
    Jpn J Clin Oncol; 2012 Jul; 42(7):637-9. PubMed ID: 22628610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
    Utecht KN; Kolesar J
    Am J Health Syst Pharm; 2008 Jul; 65(13):1221-31. PubMed ID: 18574011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
    Laubach JP; Moslehi JJ; Francis SA; San Miguel JF; Sonneveld P; Orlowski RZ; Moreau P; Rosiñol L; Faber EA; Voorhees P; Mateos MV; Marquez L; Feng H; Desai A; van de Velde H; Elliott J; Shi H; Dow E; Jobanputra N; Esseltine DL; Niculescu L; Anderson KC; Lonial S; Richardson PG
    Br J Haematol; 2017 Aug; 178(4):547-560. PubMed ID: 28466536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of foxhole-shaped left ventricular abnormality induced by complete atrioventricular block with delayed recovery of wall motion].
    Saito M; Hayashi Y; Sasaki O; Inoue M; Fujioka S; Kouno M
    Nihon Ronen Igakkai Zasshi; 2004 Sep; 41(5):546-51. PubMed ID: 15515738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
    Zobniw CM; Saad SA; Kostoff D; Barthel BG
    Pharmacotherapy; 2014; 34(4):e18-21. PubMed ID: 24338786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
    Thuillier D; Lenglet A; Chaby G; Royer R; Vaida I; Viseux V; Dadban A; Billet A; Christophe O; Chatelain D; Marolleau JP; Lok C; Damaj G
    Ann Dermatol Venereol; 2009 May; 136(5):427-30. PubMed ID: 19442799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Jackson G; Einsele H; Moreau P; Miguel JS
    Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.
    Łuczak M; Kubicki T; Rzetelska Z; Szczepaniak T; Przybyłowicz-Chalecka A; Ratajczak B; Czerwińska-Rybak J; Nowicki A; Joks M; Jakubowiak A; Komarnicki M; Dytfeld D
    Pol Arch Intern Med; 2017 Jun; 127(6):392-400. PubMed ID: 28546528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
    Yazbeck V; Shafer D; Perkins EB; Coppola D; Sokol L; Richards KL; Shea T; Ruan J; Parekh S; Strair R; Flowers C; Morgan D; Kmieciak M; Bose P; Kimball A; Badros AZ; Baz R; Lin HY; Zhao X; Reich RR; Tombes MB; Shrader E; Sankala H; Roberts JD; Sullivan D; Grant S; Holkova B
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):569-575.e1. PubMed ID: 30122201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
    Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
    Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.